Thomas Lingelbach, Valneva CEO

Covid-19 roundup: EMA of­fers ear­ly ac­cess to Pfiz­er's pill Paxlovid; Val­ne­va fires back with boost­er da­ta of its own

The EMA said Thurs­day that Eu­ro­pean coun­tries can be­gin to use Pfiz­er’s Covid-19 treat­ment pill Paxlovid, even though it is not yet au­tho­rized in the EU.

The pill is in­di­cat­ed to treat adults with Covid-19 who do not re­quire sup­ple­men­tal oxy­gen and who are at in­creased risk of pro­gress­ing to se­vere dis­ease.

The ear­ly ad­vice is based on clin­i­cal tri­al da­ta from Pfiz­er show­ing 1% of pa­tients (6 out of 607) who took Paxlovid with­in five days of the start of symp­toms were hos­pi­talised with­in 28 days of start­ing treat­ment com­pared with 6.7% of pa­tients (41 out of 612) giv­en place­bo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.